Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
Conditions
- Primary Immune Thrombocytopenia
Interventions
- DRUG: 2.5mg/d Hetrombopag
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators